Tagged with OBI

UK Three years into his role as general manager of Sobi’s UK and Republic of Ireland operations, Neil Dugdale introduces the scope of operations of the Swedish rare disease player to our audience, highlighting the company’s unique positioning in working closely with patient groups to drive forward better understanding of unmet…

Canada Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering from rare diseases, while emphasizing the importance of an adequate rare disease framework to streamline this process in the future.…

Canada Michel Fortin, president and CEO of Prevtec Microbia, a global biotech player founded in Saint-Hyacinthe, outside of Montréal, analyzes the opportunities in the global animal health industry, and how Prevtec Microbia has positioned itself to seize those by developing technologies that are alternatives to the usage of antibiotics in animal…

Brazil Cristina Dislich Ropke, CEO of Phytobios, a company that helps multinational and local companies turn Brazilian biodiversity into medicinal products, highlights the company’s exceptional perseverance in studying the Brazilian biodiversity at times when legal uncertainties threatened the development of this segment. She also expands on the drug development center founded…

Brazil Jaime Rabi, director of Microbiológica, documents the unique development path of the company and its pioneering contribution to the production of antiretroviral medicines in Brazil, as well as its international partnerships with American success-stories like Pharmasset, which originally developed the breakthrough therapy sofosbuvir. He also provides insights into the remarkable…

Austria Arnoldas Doviltis, general manager of Ferring Austria, a research-driven Swiss biopharmaceutical company, elaborates on the autonomous nature of local Ferring affiliates and how this allows a tailored approach to conduct Austrian operations. Furthermore, he provides an insight into the peculiarities of market access within Austria compared to other European nations…

Colombia Aurobindo’s regional head, Kamlesh Thakkar, discusses how the company is truly benefiting the healthcare landscape in Colombia, while describing his experience in changing the mindset concerning the use of generics in the top hospitals of the country and shares the origins of Aurobindo’s healthier life campaign. To begin, Mr. Thakkar,…

Taiwan In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug development process. She also elaborates on the key next steps that lie ahead for OBI Pharma’s flagship immuno-oncology therapy, Adagloxad…

Mexico Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s region-wide commitment to offering reliable, compliant and sustainable APIs. Could you please introduce to our international audience the key activities…

Switzerland Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to guarantee supplies by building a robust network; and why manufacturing is where dreams become reality, taking the results from a…

Pharma Sandra Sánchez, General Manager at PROBIOMED, explains the crucial role that biosimilars will play in the future healthcare system as well as the importance of complying with COFEPRIS’ regulations to expand PROBIOMED’s business within the region. Last time we met with you, you explained that PROBIOMED was following a three…

Pharma Luigi Boggio, President of Assobiomedica, the association representing the medtech industry, and MD of B. Braun Italy, calls on the Italian government to implement a national system that measures the impact of medtech innovations. What are the exact activities of Assobiomedica and what are your main priorities as President? The…